Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Iterum Therapeutics Plc (ITRM)

Iterum Therapeutics Plc (ITRM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Iterum Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA Globe Newswire - Mon Jul 11, 2022

--SPA supports protocol for Phase 3 Clinical Trial of Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections-- --Clinical Trial...

ITRM : 1.2500 (+2.46%)
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire - Wed Jul 6, 2022

DUBLIN, Ireland and CHICAGO, July 06, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical...

ITRM : 1.2500 (+2.46%)
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire - Tue Jun 14, 2022

DUBLIN, Ireland and CHICAGO, June 14, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical...

ITRM : 1.2500 (+2.46%)
Iterum Therapeutics Reports First Quarter 2022 Financial Results Globe Newswire - Fri May 13, 2022

-General Alignment with FDA on Key Aspects of Design of Proposed Additional Clinical Trial- -Cash Runway into 2024- DUBLIN, Ireland and CHICAGO, May ...

ITRM : 1.2500 (+2.46%)
Iterum Therapeutics Provides Regulatory Update Globe Newswire - Wed May 11, 2022

DUBLIN, Ireland and CHICAGO, May 11, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical...

ITRM : 1.2500 (+2.46%)
Iterum Therapeutics Presented Data at the 32nd European Congress of Clinical Microbiology and Infectious Diseases Globe Newswire - Mon Apr 25, 2022

DUBLIN, Ireland and CHICAGO, April 25, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical...

ITRM : 1.2500 (+2.46%)
Iterum Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results Globe Newswire - Mon Mar 28, 2022

--Registration Trial for uUTI Planned in Second Half of 2022----Cash Runway into 2024-- --Company to host conference call today at 8:30am ET-- DUBLIN,...

ITRM : 1.2500 (+2.46%)
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire - Tue Feb 8, 2022

DUBLIN, Ireland and CHICAGO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical...

ITRM : 1.2500 (+2.46%)
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire - Tue Dec 14, 2021

DUBLIN, Ireland and CHICAGO, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical...

ITRM : 1.2500 (+2.46%)
Iterum Therapeutics Appoints Sailaja Puttagunta, MD as Chief Medical Officer Globe Newswire - Mon Dec 13, 2021

DUBLIN, Ireland and CHICAGO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage...

ITRM : 1.2500 (+2.46%)

Barchart Exclusives

5 'Pick and Shovel' AI Growth Stocks to Scoop Up Now Barchart - 1 hour ago
With AI demand rising and data centers set for explosive growth, these AI infrastructure providers emerge as prime investment opportunities now. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot